|
KMID : 1148920140480030187
|
|
Nuclear Medicine and Molecular Imaging
2014 Volume.48 No. 3 p.187 ~ p.195
|
|
|
Prognostic Value of Metabolic Tumor Volume Estimated by 18?F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease
|
|
Kim Ji-Hyun
Hong Jun-Shik
Kim Seog-Gyun
Hwang Kyung-Hoon
Kim Min-Su
Ahn Hee-Kyung
Sym Sun-Jin
Park Jinny
Cho Eun-Kyung
Shin Dong-Bok
Lee Jae-Hoon
|
|
|
Abstract
|
|
|
Purpose: The purpose of this study was to evaluate the prognostic value of metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-containing immunochemotherapy.
Methods: Patients with newly diagnosed DLBCL who underwent pre-treatment torso FDG-PET/CT scan taken within 10 days before treatment were included. MTV was defined as the volume of hypermetabolic tissue with a standardized uptake value (SUV) greater than a threshold value of 2.5 and calculated using volume viewer software. Association of MTV with patient characteristics and survival were compared.
Results: A total of 96 patients were evaluated. During a median follow-up period of 27.8 months, 3-year event-free survival (EFS) and overall survival was 69.5 % and 72.9 %, respectively. The Ann Arbor staging showed a limitation of prognosis because there was no difference of EFS between patients with Ann Arbor stage II and those with stage III. On the contrary, among patients with Ann Arbor stage II or III disease (n?=?53), the higher MTV group showed significantly inferior EFS compared with the lower MTV group.
Conclusions: In the current study, we identified the pre-treatment MTV measured by FDG-PET/CT as a potential predictor of survival in patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP), at least in Ann Arbor stage II and III disease.
|
|
|
KEYWORD
|
|
|
Diffuse large cell lymphoma, Metabolic tumor volume, Tumor burden, Prognosis, Positron-emission tomography
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|